{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:23:31Z","timestamp":1777922611008,"version":"3.51.4"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Plan Nacional de Drogas Research","award":["2005-Orden sco\/3246\/2004"],"award-info":[{"award-number":["2005-Orden sco\/3246\/2004"]}]},{"name":"SENY Fundaci\u00f3","award":["CI 2005\u20130308007"],"award-info":[{"award-number":["CI 2005\u20130308007"]}]},{"name":"Fundaci\u00f3n Marqu\u00e9s de Valdecilla","award":["API07\/011"],"award-info":[{"award-number":["API07\/011"]}]},{"name":"Gerencia Regional de Salud de Castilla y Le\u00f3n","award":["INT\/M\/04\/17"],"award-info":[{"award-number":["INT\/M\/04\/17"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1093\/ijnp\/pyy082","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T15:14:04Z","timestamp":1536592444000},"page":"1090-1101","source":"Crossref","is-referenced-by-count":20,"title":["Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-3801","authenticated-orcid":false,"given":"Marcos","family":"G\u00f3mez-Revuelta","sequence":"first","affiliation":[{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Pelayo-Ter\u00e1n","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Psiquiatr\u00eda y Salud Mental, Hospital El Bierzo, Servicio de Salud de Castilla y Le\u00f3n, Ponferrada (Le\u00f3n), Spain"},{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Juncal-Ruiz","sequence":"additional","affiliation":[{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Ortiz-Garc\u00eda de la Foz","sequence":"additional","affiliation":[{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"V\u00e1zquez-Bourgon","sequence":"additional","affiliation":[{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonz\u00e1lez-Pinto","sequence":"additional","affiliation":[{"name":"Hospital Universitario de \u00c1lava, Osakidetza, Department of Psychiatry, UPV-EHU, Vitoria-Gasteiz, Spain"},{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicto","family":"Crespo-Facorro","sequence":"additional","affiliation":[{"name":"CIBERSAM, Centro Investigaci\u00f3n Biom\u00e9dica en Red Salud Mental, Madrid, Spain"},{"name":"University Hospital Marqu\u00e9s de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,12]]},"reference":[{"key":"key\n\t\t\t\t2018120305422691400_CIT0001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary depression scale","author":"Addington","year":"1993","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0002","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"116","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0003","volume-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000291496","article-title":"Scale for the Assessment of Negative Symptoms (SANS)","volume":"155","author":"Andreasen","year":"1989","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006625.pub3","article-title":"Quetiapine versus other atypical antipsychotics for schizophrenia","author":"Asmal","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0006","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0008","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","article-title":"Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study","volume":"46","author":"Caseiro","year":"2012","journal-title":"J Psychiatr Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2007.09.008","article-title":"The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain","volume":"23","author":"Ciudad","year":"2008","journal-title":"Eur Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2392-3","article-title":"Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis","volume":"219","author":"Crespo-Facorro","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0011","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.schres.2013.04.014","article-title":"Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial","volume":"147","author":"Crespo-Facorro","year":"2013","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00213-013-3241-3","article-title":"Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year","volume":"231","author":"Crespo-Facorro","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2013.05.016","article-title":"The evidence for illness progression after relapse in schizophrenia","volume":"148","author":"Emsley","year":"2013","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-244X-13-50","article-title":"The nature of relapse in schizophrenia","volume":"13","author":"Emsley","year":"2013","journal-title":"BMC Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0015","volume-title":"Structured clinical interview for DSM-IV-TR axis I disorders research version, patient edition with psychotic screen (SCID-I\/P)","author":"First","year":"2002"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","article-title":"Relapse prevention in first-episode schizophrenia\u2013maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the german research network on schizophrenia","volume":"72","author":"Gaebel","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","article-title":"Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review","volume":"36","author":"Garc\u00eda","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0018","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0019","doi-asserted-by":"crossref","first-page":"h2435","DOI":"10.1136\/bmj.h2435","article-title":"Does long term use of psychiatric drugs cause more harm than good","volume":"350","author":"Gotzsche","year":"2015","journal-title":"Bmj"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0020","volume-title":"Ecdeu assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare publication ADM 76338","author":"Guy","year":"1976"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40263-018-0531-7","article-title":"Long-acting injectable second-generation antipsychotics: an update and comparison between agents","volume":"32","author":"Jann","year":"2018","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-8-31","article-title":"Effectiveness of second generation antipsychotics: a systematic review of randomized trials","volume":"8","author":"Johnsen","year":"2008","journal-title":"BMC Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0024","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s00213-017-4646-1","article-title":"Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment","volume":"234","author":"Juncal-Ruiz","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0025","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eurpsy.2007.03.002","article-title":"A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study","volume":"22","author":"Kerwin","year":"2007","journal-title":"Eur Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0027","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","article-title":"Estimating dopamine D\u2082 receptor occupancy for doses of 8 antipsychotics: a meta-analysis","volume":"33","author":"Lako","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0028","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","article-title":"Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies","volume":"211","author":"Lally","year":"2017","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0029","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.pnpbp.2010.12.003","article-title":"A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone","volume":"35","author":"Lee","year":"2011","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0030","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0031","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0032","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/ps.2008.59.5.487","article-title":"Science and recovery in schizophrenia","volume":"59","author":"Lieberman","year":"2008","journal-title":"Psychiatr Serv"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jad.2017.02.012","article-title":"Maintenance therapy with second generation antipsychotics for bipolar disorder. A systematic review and meta-analysis","volume":"213","author":"Lindstr\u00f6m","year":"2017","journal-title":"J Affect Disord"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0036","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4088\/JCP.14m09540","article-title":"Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study","volume":"77","author":"Mayoral-van Son","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0037","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0038","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1017\/S0033291706007951","article-title":"A systematic review of longitudinal outcome studies of first-episode psychosis","volume":"36","author":"Menezes","year":"2006","journal-title":"Psychol Med"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0039","doi-asserted-by":"crossref","first-page":"e1001861","DOI":"10.1371\/journal.pmed.1001861","article-title":"Antipsychotic maintenance treatment: time to rethink","volume":"12","author":"Moncrieff","year":"2015","journal-title":"Plos Med"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2007.04.035","article-title":"Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia","volume":"98","author":"Mullins","year":"2008","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0041","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.bp.116.182683","article-title":"Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics","volume":"209","author":"Murray","year":"2016","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0042","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e3182962480","article-title":"Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability","volume":"33","author":"Noguera","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0043","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0044","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in cantabria: insights from the clinical programme on early phases of psychosis","volume":"2","author":"Pelayo-Ter\u00e1n","year":"2008","journal-title":"Early Interv Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological treatments for first-episode schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0046","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0047","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ajp.2015.14101329","article-title":"Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review","volume":"172","author":"Samara","year":"2015","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0048","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.psychres.2012.07.005","article-title":"One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis","volume":"200","author":"San","year":"2012","journal-title":"Psychiatry Res"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0049","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/YCO.0b013e328336662e","article-title":"Redefining outcome measures in schizophrenia: integrating social and clinical parameters","volume":"23","author":"Shrivastava","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0051","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/acps.12641","article-title":"Real-world effectiveness of antipsychotics","volume":"134","author":"Tiihonen","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0052","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0053","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0054","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/acps.12621","article-title":"Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study","volume":"134","author":"Vanasse","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-017-4763-x","article-title":"Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-na\u00efve patients with a first-episode of non-affective psychosis","volume":"235","author":"V\u00e1zquez-Bourgon","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0056","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0057","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0058","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0059","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2215-0366(17)30270-5","article-title":"Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses","volume":"4","author":"Zhu","year":"2017","journal-title":"The Lancet Psychiatry"},{"key":"key\n\t\t\t\t2018120305422691400_CIT0060","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.schres.2013.08.001","article-title":"Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review","volume":"152","author":"Zipursky","year":"2014","journal-title":"Schizophr Res"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/21\/12\/1090\/26947358\/pyy082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T21:27:01Z","timestamp":1571866021000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/21\/12\/1090\/5095916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,9,12]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyy082","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,9,12]]}}}